598 related articles for article (PubMed ID: 28002268)
1. CHOROIDAL THICKNESS AS A PROGNOSTIC FACTOR OF PHOTODYNAMIC THERAPY WITH AFLIBERCEPT OR RANIBIZUMAB FOR POLYPOIDAL CHOROIDAL VASCULOPATHY.
Sakurada Y; Sugiyama A; Tanabe N; Kikushima W; Kume A; Iijima H
Retina; 2017 Oct; 37(10):1866-1872. PubMed ID: 28002268
[TBL] [Abstract][Full Text] [Related]
2. Initial treatment for polypoidal choroidal vasculopathy: Ranibizumab combined with photodynamic therapy or fixed-dosing aflibercept monotherapy.
Yoneda A; Wakiyama H; Kurihara J; Kitaoka T
Eur J Ophthalmol; 2020 Nov; 30(6):1473-1479. PubMed ID: 31476891
[TBL] [Abstract][Full Text] [Related]
3. One-year outcome of combination therapy with intravitreal aflibercept and verteporfin photodynamic therapy for polypoidal choroidal vasculopathy.
Matsumiya W; Honda S; Otsuka K; Miki A; Nagai T; Imai H; Kusuhara S; Nakamura M
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):541-548. PubMed ID: 27687988
[TBL] [Abstract][Full Text] [Related]
4. Short-term focal macular electroretinogram of eyes treated by aflibercept & photodynamic therapy for polypoidal choroidal vasculopathy.
Takayama K; Kaneko H; Kataoka K; Ueno S; Chang-Hua P; Ito Y; Terasaki H
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):449-455. PubMed ID: 27538907
[TBL] [Abstract][Full Text] [Related]
5. Combined reduced fluence photodynamic therapy and intravitreal ranibizumab for polypoidal choroidal vasculopathy.
Ricci F; Calabrese A; Regine F; Missiroli F; Ciardella AP
Retina; 2012 Jul; 32(7):1280-8. PubMed ID: 22218148
[TBL] [Abstract][Full Text] [Related]
6. Subfoveal choroidal thickness in polypoidal choroidal vasculopathy after switching to intravitreal aflibercept injection.
Saito M; Kano M; Itagaki K; Ise S; Imaizumi K; Sekiryu T
Jpn J Ophthalmol; 2016 Jan; 60(1):35-41. PubMed ID: 26350229
[TBL] [Abstract][Full Text] [Related]
7. Two-year results of a treat-and-extend regimen with aflibercept for polypoidal choroidal vasculopathy.
Morimoto M; Matsumoto H; Mimura K; Akiyama H
Graefes Arch Clin Exp Ophthalmol; 2017 Oct; 255(10):1891-1897. PubMed ID: 28669041
[TBL] [Abstract][Full Text] [Related]
8. Comparison of initial treatment between 3-monthly intravitreal aflibercept monotherapy and combined photodynamic therapy with single intravitreal aflibercept for polypoidal choroidal vasculopathy.
Kikushima W; Sakurada Y; Sugiyama A; Tanabe N; Kume A; Iijima H
Graefes Arch Clin Exp Ophthalmol; 2017 Feb; 255(2):311-316. PubMed ID: 27534663
[TBL] [Abstract][Full Text] [Related]
9. Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy.
Saito M; Iida T; Kano M
Retina; 2012 Jul; 32(7):1272-9. PubMed ID: 22547209
[TBL] [Abstract][Full Text] [Related]
10. Comparison of the effects of photodynamic therapy, intravitreal ranibizumab and combination for polypoidal choroidal vasculopathy under 1 + PRN regimen.
Lai K; Li Y; Zhou L; Zhong X; Huang C; Xu F; Lu L; Ge J; Jin C
BMC Ophthalmol; 2018 Jun; 18(1):144. PubMed ID: 29925341
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors after aflibercept therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy.
Ogasawara M; Koizumi H; Yamamoto A; Itagaki K; Saito M; Maruko I; Okada AA; Iida T; Sekiryu T
Jpn J Ophthalmol; 2018 Sep; 62(5):584-591. PubMed ID: 29974277
[TBL] [Abstract][Full Text] [Related]
12. COMPARISON OF OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHIC CHANGES AFTER ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR THERAPY ALONE OR IN COMBINATION WITH PHOTODYNAMIC THERAPY IN POLYPOIDAL CHOROIDAL VASCULOPATHY.
Teo KYC; Yanagi Y; Lee SY; Yeo IYS; Tan GSW; Mathur R; Chan CM; Wong TY; Cheung CMG
Retina; 2018 Sep; 38(9):1675-1687. PubMed ID: 28767554
[TBL] [Abstract][Full Text] [Related]
13. Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab.
Saito M; Kano M; Itagaki K; Oguchi Y; Sekiryu T
Retina; 2014 Nov; 34(11):2192-201. PubMed ID: 25077530
[TBL] [Abstract][Full Text] [Related]
14. Association of an age-related maculopathy susceptibility 2 gene variant with the 12-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Nakai S; Matsumiya W; Miki A; Honda S; Nakamura M
Jpn J Ophthalmol; 2019 Sep; 63(5):389-395. PubMed ID: 31376050
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of fixed-dosing aflibercept for treating polypoidal choroidal vasculopathy: 1-year results of the VAULT study.
Lee JE; Shin JP; Kim HW; Chang W; Kim YC; Lee SJ; Chung IY; Lee JE;
Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):493-502. PubMed ID: 27628062
[TBL] [Abstract][Full Text] [Related]
16. REDUCED VASCULAR DENSITY IN THE CHOROID AFTER TREATMENT WITH PHOTODYNAMIC THERAPY COMBINED WITH AFLIBERCEPT IN PATIENTS WITH POLYPOIDAL CHOROIDAL VASCULOPATHY.
Mukai R; Matsumoto H; Miyakubo T; Akiyama H
Retina; 2021 Jan; 41(1):156-161. PubMed ID: 32251239
[TBL] [Abstract][Full Text] [Related]
17. The 24-month outcomes of intravitreal aflibercept combined with photodynamic therapy for polypoidal choroidal vasculopathy.
Nakai S; Matsumiya W; Keiko O; Miki A; Nakamura M; Honda S
Jpn J Ophthalmol; 2019 Jan; 63(1):100-108. PubMed ID: 30406511
[TBL] [Abstract][Full Text] [Related]
18. Effects of photodynamic therapy plus intravitreal aflibercept with subtenon triamcinolone injections for aflibercept-resistant polypoidal choroidal vasculopathy.
Sakai T; Kato N; Kubota M; Tsuneoka H
Graefes Arch Clin Exp Ophthalmol; 2017 Aug; 255(8):1565-1571. PubMed ID: 28601912
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Ranibizumab With or Without Verteporfin Photodynamic Therapy for Polypoidal Choroidal Vasculopathy: A Randomized Clinical Trial.
Koh A; Lai TYY; Takahashi K; Wong TY; Chen LJ; Ruamviboonsuk P; Tan CS; Feller C; Margaron P; Lim TH; Lee WK;
JAMA Ophthalmol; 2017 Nov; 135(11):1206-1213. PubMed ID: 28983556
[TBL] [Abstract][Full Text] [Related]
20. Timing of Complete Polypoidal Regression after Intravitreous Aflibercept Treatments in Polypoidal Choroidal Vasculopathy.
Chaikitmongkol V; Upaphong P; Patikulsila D; Jirarattanasopa P; Choovuthayakorn J; Watanachai N; Kunavisarut P; Ratanasukon M; Bhurayanontachai P; Ingviya T; Bressler SB; Bressler NM
Ophthalmol Retina; 2022 Jan; 6(1):21-28. PubMed ID: 33781929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
